This partnership
is personal

Accurate solutions aimed at altering the face and future of cancer

Genomics in Drug Development

Next-generation sequencing (NGS) enables researchers and drug developers to better understand the biology that drives cancer predisposition and proliferation. These insights have led to the development of targeted therapeutics and multi-analyte tumor analysis. This, in turn, has opened the door for novel methods to monitor cancer treatment and recurrence.

lllumina brings innovation to oncology drug development by offering comprehensive genomic solutions and working in collaboration with leading pharmaceutical providers.

Companion Diagnostics Development

As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.

Learn More
NGS for Drug Development

NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.

Learn More
Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
How Genomics is Shaping the Future of Oncology
How Genomics is Shaping the Future of Oncology

Read an interview with John Leite, VP of Marketing for Illumina’s Oncology business.

Read Interview
Immunotherapy Research and NGS
Immunotherapy Research and NGS

An overview of exciting new fields of immunotherapy research, and how NGS helps to move them forward.

View PDF
NGS Used for Biological QC in BioPharma Production
NGS Used for Biological QC in BioPharma Production

Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.

Access PDF
Services and Providers
Services and Providers

Explore services and service providers for a broad range of genotyping, gene expression, and sequencing applications.

Explore Services
Celebrate the Genome
Celebrate the Genome

Reflect what the power of the genome means for drug development and share it. Educate others. Promote the promise of the genome.

Learn More